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Abstract
Background: There are few published estimates of the cost of pediatric antiretroviral therapy (ART) in Africa. Our objective
was to estimate the outpatient cost of providing ART to children remaining in care at six public sector clinics in Zambia
during the first three years after ART initiation, stratified by service delivery site and time on treatment.
Methods: Data on resource utilization (drugs, diagnostics, outpatient visits, fixed costs) and treatment outcomes (in care,
died, lost to follow up) were extracted from medical records for 1,334 children at six sites who initiated ART at ,15 years of
age between 2006 and 2011. Fixed and variable unit costs (reported in 2011 USD) were estimated from the provider’s
perspective using site level data.
Results: Median age at ART initiation was 4.0 years; median CD4 percentage was 14%. One year after ART initiation, 73% of
patients remained in care, ranging from 60% to 91% depending on site. The average annual outpatient cost per patient
remaining in care was $209 (95% CI, $199–$219), ranging from $116 (95% CI, $107–$126) to $516 (95% CI, $499–$533)
depending on site. Average annual costs decreased as time on treatment increased. Antiretroviral drugs were the largest
component of all outpatient costs (.50%) at four sites. At the two remaining sites, outpatient visits and fixed costs together
accounted for .50% of outpatient costs. The distribution of costs is slightly skewed, with median costs 3% to 13% lower
than average costs during the first year after ART initiation depending on site.
Conclusions: Outpatient costs for children initiating ART in Zambia are low and comparable to reported outpatient costs for
adults. Outpatient costs and retention in care vary widely by site, suggesting opportunities for efficiency gains. Taking
advantage of such opportunities will help ensure that targets for pediatric treatment coverage can be met.
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Introduction
At the end of 2010, 456,000 children in low- and middle-
income countries were reported to be on antiretroviral therapy
(ART) for HIV/AIDS, representing only 23% of children in need
of ART [1]. Although pediatric ART coverage lags adult coverage
substantially, an ever-increasing proportion of HIV-infected
children are initiating ART each year, of whom some 85% live
in sub-Saharan Africa [1]. Treatment outcomes for these children
vary widely but are generally encouraging [2]. In Zambia, a low-
middle income country in southern Africa where 25,388 children
were reported to be on ART and another 72,612 children were
reported to be in need of ART in 2010 [1], several papers have
reported on good clinical, immunologic, and virologic outcomes
for children through two years after ART initiation [3,4].
Recent research on the outcomes of pediatric ART in Africa has
not been matched by research on the costs of treatment. A review
of the costs of HIV treatment in developing countries published in
2011 found one published study that reported pediatric HIV costs
and we are aware of only two studies published since then
[5,6,7,8]. No published estimates exist for Zambia. For Ministries
of Health, funding agencies, and others responsible for provision of
medical services and ensuring sufficient resources to achieve
national and international HIV response goals, there is effectively
no information available about this important component of
national treatment programs.
PLOS ONE | www.plosone.org 1 June 2013 | Volume 8 | Issue 6 | e67910
To contribute to efforts to deliver HIV services more efficiently
and ensure that sufficient resources are available for treatment
programs to be sustained, we estimated the outpatient costs of
providing ART to children attending six public sector clinics in
Zambia during the first three years after ART initiation, stratified
by service delivery site and time on treatment.
Methods
Ethics Statement
The Boston University Medical Center Institutional Review
Board and the University of Zambia Research Ethics Committee
provided ethical approval of the study (protocol numbers H-28104
and 008-04-09). A waiver of informed consent was granted by
both committees because the study was a retrospective review of
routinely collected information from patient medical records.
Analytic Overview
We used previously published methods to estimate average
annual outpatient costs per patient for the total cohort and for the
subset remaining in care [8,9,10]. We used retrospective cohort
data from outpatient medical records on patient outcomes and
resource utilization and site-level data on unit costs. Resources
utilized included antiretroviral (ARV) drugs, laboratory tests,
outpatient visits, and fixed costs (e.g., buildings and infrastructure,
equipment, supplies). Costs were calculated from the provider’s
perspective in 2011 US dollars.
Study Sites
We purposively selected six study sites intended to represent
specific models or settings for pediatric ART delivery in Zambia
(Table 1). Sites included a health center in Lusaka Province (site 1),
a second-level general hospital in Western Province (site 2), a
pediatric center of excellence operating within a second-level
general hospital in Southern Province (site 3), a second-level
general hospital in Copperbelt Province (site 4), a second-level
mission hospital in Southern Province (site 5), and a first-level
district hospital in Southern Province (site 6). All sites were public
sector clinics funded primarily by the Government of Zambia and
providing ART services to patients free of charge. The number of
active adult and pediatric patients enrolled in the ART program at
each site in 2010 ranged from 827 at site 3, which sees pediatric
patients only, to 6,640 at site 2.
Sample Selection
At each study site, up to three retrospective cohorts of 120
children each who initiated ART at the site at least 12, 24, or 36
months prior to data collection were selected consecutively from
clinic registers and enrolled in the study. Due to low patient
volume at the study sites, the resulting cohorts overlapped,
creating a single cohort of study subjects who initiated ART at
least 12 months prior to data collection at each site. Data for each
subject was censored at 12, 24, or 36 months after ART initiation,
allowing between 12 and 36 months of follow up for each study
subject.
Eligible study subjects were children between 0 and 14 years of
age at ART initiation who were not known to have transferred to
another clinic during the study follow up period. Medical eligibility
for ART initiation followed Zambian national guidelines prevail-
ing during the study period and included initiation irrespective of
CD4 or WHO clinical stage for all children under 12 months of
age, initiation irrespective of CD4 for children $12 months of age
with WHO clinical stage 3 or 4, and initiation according to CD4
cell count or total lymphocyte count thresholds for children $12
months of age with WHO clinical stage 1 or 2 [11].
Data Collection
Data on resources used during the first 12, 24, or 36 months
following ART initiation were obtained from each study subject’s
medical record. With the exception of non-ARV drugs, all
resources used by the provider to provide outpatient care to study
subjects were included, even if the resource cost was borne by
another entity (e.g., by an external funder). Non-ARV drugs were
excluded because of the poor quality of information recorded in
the study subjects’ medical records. Fixed and variable unit costs
for resources utilized were estimated from site-level financial
records, interviews with site managers, national drug price lists,
and market prices.
Classification of Patient Outcomes
Each study subject was assigned to an outcome category at the
end of 12 months. Those with sufficient follow up were also
assigned to outcome categories after 24 and 36 months on ART.
Outcomes were defined on the basis of subject status at the study
site and included in care, known to have died, and lost to follow up.
Subjects were classified as known to have died if a confirmation of
death was noted in their medical record before the 12-, 24-, or 36-
month study endpoint. Subjects who were three or more months
late for their last scheduled consultation or medication pickup
before the 12-, 24-, or 36-month study endpoint but had no
confirmation of death in their medical record were classified as lost
to follow up. Subjects not classified as known to have died or lost to
follow up were classified as in care.
Cost Estimates
Fixed and variable unit costs used in the analysis included costs
incurred at the site reported in Zambian Kwacha (ZMK) adjusted
to 2011 levels using the country’s consumer price index [12]. All
costs were converted to US dollars at a rate of 4,861 ZMK/$, the
average exchange rate for 2011 [13].
Fixed costs were defined as costs for resources used to treat
study subjects that could not be attributed directly to an individual
subject’s care, such as buildings, equipment, and support staff in
the ART clinic. For equipment and buildings, upfront investment
costs were estimated using a replacement cost approach. These
costs were annualized using a 3% discount rate and an estimated
working life (50 years for buildings, 5 years for equipment) [14].
The annual cost of support staff employed in the ART clinic at the
study sites during the study period was based on 2011 salaries and
allowances. The total annual fixed cost for each site was estimated
and then divided by the total number of active patients at the site
during each year to produce an average fixed cost per patient-year
in care.
Variable costs were defined as costs for resources used to treat
study subjects that could be attributed directly to an individual
subject or visit, such as ARV drugs, laboratory tests, and provider
time for clinic visits. ARV drug costs were estimated as the average
per unit cost for all units of a particular drug purchased for the
Zambia national HIV program in 2011, or during the most recent
year available if no units of a particular drug were purchased in
2011, as reported by the Global Price Reporting Mechanism [15].
Data on ART regimen dispensed and patient weight at each visit
were used to determine the appropriate drug formulation (fixed
dose tablet, single dose tablet, or syrup) and dose for each ARV
drug dispensed [11]. Laboratory test costs were estimated as the
sum of unit costs for reagents, consumables, equipment, labor, and
space. Costs of reagents and consumables were estimated from
Costs and Outcomes of Pediatric ART
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standard Zambian Ministry of Health per package costs [16].
Annual laboratory equipment, labor, and space costs were divided
by the total number of laboratory tests performed per year to
estimate a per test cost at each site. Provider time was valued on a
per visit basis. The cost per visit was estimated by dividing the total
cost of staff time for each type of provider conducting patient
consultations, valued at 2011 salaries and allowances, by the total
number of patient consultations with each provider type per year.
Costs for outpatient care above the level of the service delivery
site (e.g., government costs of oversight or training) and costs to the
patients (e.g., clinic fees, transport, caregiver time associated with
child visits) were excluded..
Data Analysis
Data were analyzed in Stata version 11. Average annual costs
per patient for the total sample were calculated at each time point
–12, 24, or 36 months after ART initiation – by dividing total costs
for the first one, two, or three years on ART for all patients by the
total number of patients in the cohort and then dividing by one,
two, or three years. Average annual costs per patient for the subset
of the sample remaining in care were calculated by dividing total
costs for the subset of the sample remaining in care by the total
number of patients remaining in care at each time point. Average
annual costs to produce a patient remaining in care at 12, 24, or
36 months after ART initiation, referred to as production costs,
were calculated by dividing the average cost for all patients in the
total sample over the first one, two, or three years on ART by the
Table 2. Patient outcomes at six ART treatment sites in Zambia by site and time on treatment.
Patient outcome, n (%) Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 All sites
12 months after ART initiation
In care 147 (79) 156 (60) 171 (74) 116 (70) 250 (91) 137 (65) 977 (73)
Known to have died 28 (15) 16 (6) 3 (1) 8 (5) 1 (0) 11 (5) 67 (5)
Lost to follow up 12 (6) 90 (34) 58 (25) 42 (25) 24 (9) 64 (30) 290 (22)
24 months after ART initiation
In care 87 (69) 107 (58) 82 (68) 67 (56) 185 (95) 92 (60) 620 (69)
Known to have died 21 (17) 14 (8) 2 (2) 7 (6) 0 (0) 9 (6) 53 (6)
Lost to follow up 18 (14) 64 (35) 36 (30) 46 (38) 10 (5) 53 (34) 227 (25)
36 months after ART initiation
In care 76 (63) 66 (55) n.a. n.a. 108 (90) 50 (56) 300 (67)
Known to have died 21 (18) 11 (9) n.a. n.a. 0 (0) 3 (3) 35 (8)
Lost to follow up 23 (19) 43 (36) n.a. n.a. 12 (10) 36 (40) 114 (25)
ART: antiretroviral therapy.
doi:10.1371/journal.pone.0067910.t002
Table 3. Average annual costs at six ART treatment sites in Zambia by site and time on treatment.
Average annual cost, 2011 USD
(95% CI) Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 All sites
12 months after ART initiation
Average annual cost per
patient for total sample
123 (114–131) 81 (73–89) 433 (408–458) 114 (102–126) 156 (148–165) 92 (84–100) 169 (161–178)
Average annual cost per patient
for subset of sample remaining
in care
148 (142–154) 116 (107–126) 516 (499–533) 151 (140–163) 165 (157–174) 125 (119–132) 209 (199–219)
24 months after ART initiation
Average annual cost per
patient for total sample
114 (102–126) 68 (60–75) 372 (343–401) 91 (78–104) 155 (148–163) 84 (74–94) 140 (131–148)
Average annual cost per
patient for subset of sample
remaining in care
152 (144–161) 105 (98–111) 457 (437–477) 142 (129–155) 158 (152–165) 126 (119–132) 181 (172–191)
36 months after ART initiation
Average annual cost per
patient for total sample
108 (95–121) 62 (52–71) n.a. n.a. 150 (142–158) 80 (67–93) 101 (95–107)
Average annual cost per
patient for subset of sample
remaining in care
149 (139–160) 102 (95–109) n.a. n.a. 155 (147–164) 125 (115–134) 137 (132–142)
ART: antiretroviral therapy; CI: confidence interval; USD: United States dollar.
doi:10.1371/journal.pone.0067910.t003
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proportion of patients remaining in care at each time point and
then dividing by one, two, or three years. All average and
production costs are reported with 95% confidence intervals.
Confidence intervals around the average cost to produce a patient
remaining in care at each site, which is a ratio of two random
variables, were estimated using bootstrapping methods.
For the subset of patients remaining in care 12 months after
initiating ART, we estimated a linear regression model of the
natural log of the total cost per patient for the first year on ART
against study site, calendar year of ART initiation, age at
initiation, nucleoside reverse transcriptase inhibitor (NRTI)
combination at initiation, and non-nucleoside reverse transcriptase
inhibitor (NNRTI) or protease inhibitor (PI) at initiation. We used
the reg command in Stata with robust standard errors. A p-value of
less than 0.05 was regarded as significant.
Results
Cohort Characteristics
A total of 1,334 patients initiating ART at the six study sites
between 2006 and 2011 were included in the retrospective cohort
(Table 1). All 1,334 patients contributed data to the 12-month
study endpoint; 900 and 449 patients contributed data to the 24-
and 36-month study endpoints respectively. The maximum
duration of follow up at sites 3 and 4 was only 24 months due
to incomplete medical records (site 3) and insufficient numbers (site
4) for patients initiated on ART at least 36 months prior to data
collection.
Median age at ART initiation was 4.0 years; median CD4
percentage was 14%. A majority of patients at all six sites initiated
on a regimen containing stavudine, lamivudine, and either
nevirapine or efavirenz, with most of the rest substituting
zidovudine for stavudine. Few patients switched from a first-line
to a second-line regimen, defined as a switch from an NNRTI-
based regimen to a PI-based regimen or vice versa, during the
study follow up period (1% switched during the first year after
ART initiation and less than 1% switched during each of the
second and third years after ART initiation).
Patient Outcomes
One year after ART initiation, 73% of patients remained in
care, 5% were known to have died, and 22% were lost to follow up
(Table 2). The proportion of patients remaining in care ranged
from 60% at site 2 to 91% at site 5. Three years after ART
initiation, 67% of patients remained in care, ranging from 55% at
site 2 to 90% at site 5.
Table 4. Ordinary least squares regression of the natural log of total per patient costs for the first year on ART against study site
and patient-specific characteristicsa.
Variable Coefficientb t P-value 95% CI
Dummy for sitec
Site 2 20.323 29.38 ,0.001 (20.391, 20.256)
Site 3 1.326 36.59 ,0.001 (1.255, 1.397)
Site 4 0.002 0.04 0.97 (20.082, 0.085)
Site 5 0.218 6.58 ,0.001 (0.153, 0.284)
Site 6 20.057 21.81 0.07 (20.118, 0.005)
Dummy for ART initiation yeard
2007 0.071 1.79 0.07 (20.007, 0.150)
2008 20.062 21.51 0.13 (20.142, 0.018)
2009 20.167 24.20 ,0.001 (20.244, 20.089)
2010 20.289 25.57 ,0.001 (20.391, 20.187)
2011 20.280 23.68 ,0.001 (20.429, 20.131)
Age at initiation in years 0.012 4.48 ,0.001 (0.007, 0.017)
Dummy for NRTI combination at ART initiatione
AZT+3TC 0.178 6.78 ,0.001 (0.126, 0.229)
Other NRTI combination 0.847 12.53 ,0.001 (0.714, 0.979)
Dummy for NNRTI/PI at ART initiationf
EFV 0.232 7.50 ,0.001 (0.171, 0.292)
Other NNRTI or PI 0.017 0.69 0.49 (20.031, 0.065)
Intercept 4.829 124.46 ,0.001 (4.753, 4.906)
3TC: lamivudine; ABC: abacavir; ART: antiretroviral therapy; AZT: zidovudine; CI: confidence interval; d4T: stavudine; EFV: efavirenz; FTC: emtricitabine; IDV: indinavir; LPV/
r: ritonavir-boosted lopinavir; NFV: nelfinavir; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NVP: nevirapine; PI:
protease inhibitor; TDF: tenofovir.
aAnalysis includes 945 patients in the subset of the sample remaining in care 12 months after ART initiation. Analysis excludes 32 patients in the subset of the sample
remaining in care 12 months after ART initiation who initiated ART with a triple NRTI regimen because they had a confirmed or presumptive diagnosis of TB.
bFor interpretation, the coefficient multiplied by 100 represents the percentage change in total costs for a one unit change in the explanatory variable.
cReference is site 1.
dReference is initiation in 2006.
eReference is initiation on a regimen containing d4T+3TC.
fReference is initiation on a regimen containing NVP. The ‘‘other’’ category includes LPV/r, IDV, and NFV.
doi:10.1371/journal.pone.0067910.t004
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Cost Per Patient
For the first year after ART initiation, the average annual cost
per patient for the total sample was $169 (95% CI, $161–$178),
ranging from $81 (95% CI, $73–$89) at site 2 to $433 (95% CI,
$408–$458) at site 3 (Table 3). The average annual cost per patient
for the subset of the sample remaining in care at 12 months was
$209 (95% CI, $199–$219), ranging from $116 (95% CI, $107–
$126) at site 2 to $516 (95% CI, $499–$533) at site 3. The
distribution of costs was slightly skewed at all six sites with median
costs 3% to 13% lower than average costs per patient for the
subset of the sample remaining in care during the first year after
ART initiation.
At five of the six sites, average annual costs per patient for the
subset of the sample remaining in care two years after ART
initiation were lower (0–11% less) than average annual costs per
patient for the subset remaining in care during the first year after
ART initiation. Average annual costs per patient for the subset of
the sample remaining in care three years after ART initiation were
essentially the same as average annual costs per patient for the
subset remaining in care during the first two years after ART
initiation at all sites.
Table 4 presents results from a regression of the natural log of
the total cost per patient for the first year on ART against site and
patient-specific variables. ART initiation in a later calendar year,
initiation at a younger age, initiation on a stavudine- and
lamivudine- containing regimen (versus a regimen containing
zidovudine and lamivudine or other NRTI combinations), and
initiation on a nevirapine-containing regimen (versus a regimen
containing efavirenz or other NNRTI or a PI), were all
significantly associated with lower total costs per patient during
the first year on ART.
Cost Breakdown
Antiretroviral drugs were the largest cost component at 4 of 6
sites, comprising between 52% (site 6) and 70% (site 2) of all
outpatient costs per patient for the subset of the sample remaining
in care during the first year after ART initiation (Table 5). At these
sites, outpatient visits were the next largest cost component,
comprising between 17% (site 2) and 31% (site 6) of all outpatient
costs, while fixed costs and laboratory tests were a smaller share of
costs per patient. At sites 3 and 5, outpatient visits and fixed costs
together made up the majority of all outpatient costs per patient
for the subset of the sample remaining in care during the first year
after ART initiation.
Production Cost
One year after ART initiation, the annual cost to produce a
patient remaining in care was $231 (95% CI, $220–$242), ranging
from $136 (95% CI, $126–$147) at site 2 to $588 (95% CI, $560–
$622) at site 3 (Table 6). Two years after ART initiation, the
annual cost to produce a patient remaining in care was $203 (95%
CI, $193–$214), ranging from $117 (95% CI, $110–$125) at site 2
to $545 (95% CI, $506–$595) at site 3.
Discussion
The lack of information available about the cost of providing
ART to children in low-income African countries limits the
capacity of policy makers and funding agencies to achieve global
targets for pediatric treatment coverage. To help fill this gap, we
estimated the average annual outpatient cost of providing ART to
children remaining in care at six public sector clinics in Zambia
during the first three years after treatment initiation, stratified by
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initiation, 73% of patients remained in care, ranging from 60% to
91% depending on study site. The average annual outpatient cost
per patient for the subset of the sample remaining in care was $209
(95% CI, $199–$219), ranging from $116 (95% CI, $107–$126) to
$516 (95% CI, $499–$533) depending on study site. This average
annual outpatient cost per patient decreased as time on treatment
increased at most sites. The distribution of costs was skewed, with
median costs 3% to 13% lower than average costs depending on
the site. ARV drugs were the largest cost component, making up
more than 50% of all outpatient costs at four of the six sites.
Outpatient visits and fixed costs made up the majority of
outpatient costs at the remaining two sites.
Some sites had higher proportions of patients retained in care
than others. While some of this variation may be due to differences
in patient characteristics, such as age at initiation or CD4
percentage at presentation, and other differences in the underlying
patient populations across sites, some may also be due to
differences in quality of care. To the extent that variation in
patient outcomes was driven by quality of care, the exceptional
patient outcomes at site 5, where 90% of patients remained in care
three years after initiating ART, suggest that there may be
potential to improve retention in care, and thereby increase
efficiency, at other sites.
Some sites also had higher costs than others and patient
outcomes were not necessarily better at sites with higher costs.
Variation in costs across sites may be due to factors including, but
not limited to, differences in the frequency of outpatient visits and
diagnostic tests performed, choice of ART regimen, staffing levels,
and patient volume. This variation again suggests opportunities to
improve efficiency. For example, at site 3, the dedicated pediatric
clinic and by far the most expensive model of care, there may be
potential to reduce costs and increase efficiency by moving to a
more integrated care model – by integrating adult and pediatric
ART services or integrating pediatric ART and other pediatric
outpatient services – where a similar level of staffing and fixed costs
could be used to serve a larger number of patients.
Some individuals also incurred markedly higher costs than
others. The skewed cost distribution at the study sites suggests that
a small number of high cost patients may be driving up the
average cost per patient remaining in care at these sites. We found
that initiation at a younger age, initiation on a stavudine- and
lamivudine-containing regimen (versus a regimen containing other
NRTI combinations), and initiation on a nevirapine-containing
regimen (versus a regimen containing another NNRTI or PI) were
all significantly associated with lower per patient costs. These
associations suggest that there may be opportunities for efficiency
gains through earlier identification and linkage to care of HIV-
infected children and increased standardization of ART regimens.
The costs we estimated for pediatric ART in Zambia are
comparable to estimates of the costs of adult ART in Zambia.
Bratt et al. estimated annual costs ranging from $278 to $523 (in
2008 US dollars) per patient for the first year on ART [17]. Tagar
et al. estimated an average cost of $278 per ART patient per year
in 2010–2011 [18]. Marseille et al. estimated a cost of $428 per
person-year of ART in on-site costs (in 2010 US dollars), and an
additional $210 per person-year of ART in off-site costs, for the
average facility in their sample [19].
There are only two other recently published studies reporting
outpatient costs of pediatric ART [6]. Menzies et al. estimated
costs for pediatric patients in four countries, including three in
Africa (Ethiopia, Nigeria, and Uganda) [6]. Average annual costs
per newly initiated pediatric ART patient ranged from $374 in
Uganda to $1,771 in Nigeria (in 2009 US dollars). Average annual
costs per established patient ranged from $454 in Uganda to
$1,564 in Nigeria. While not strictly comparable to our results –
this study included costs of administration and management above
the site level – the estimates from other countries suggest that there
is a large amount of variation in pediatric treatment costs between
countries as well as between sites. Meyer-Rath et al. estimated the
cost of providing pediatric ART during the first two years after
ART initiation at two sites in South Africa [8]. Costs were
estimated using methods comparable to those in our study and
Table 6. Average annual cost to produce a patient in care at six ART treatment sites in Zambia by site and time on treatment.
Average annual cost, 2011 USD
(95% CI) Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 All sites
12 months after ART initiation
Average annual cost per patient for
total sample
123 (114–131) 81 (73–89) 433 (408–458) 114 (102–126) 156 (148–165) 92 (84–100) 169 (161–178)
% of total sample remaining in care 79 60 74 70 91 65 73
Average annual cost to produce a
patient remaining in care
156 (149–164) 136 (126–147) 588 (560–622) 164 (150–177) 172 (163–181) 142 (134–153) 231 (220–242)
24 months after ART initiation
Average annual cost per patient for
total sample
114 (102–126) 68 (60–75) 372 (343–401) 91 (78–104) 155 (148–163) 84 (74–94) 140 (131–148)
% of total sample remaining in care 69 58 68 56 95 60 69
Average annual cost to produce a
patient remaining in care
165 (155–176) 117 (110–125) 545 (506–595) 164 (148–183) 164 (156–172) 141 (132–152) 203 (193–214)
36 months after ART initiation
Average annual cost per patient for
total sample
108 (95–121) 62 (52–71) n.a. n.a. 150 (142–158) 80 (67–93) 101 (95–107)
% of total sample remaining in care 63 55 n.a. n.a. 90 56 67
Average annual cost to produce a
patient remaining in care
171 (155–187) 111 (104–121) n.a. n.a. 167 (157–178) 142 (129–159) 151 (145–159)
ART: antiretroviral therapy; CI: bootstrapped confidence interval; USD: United States dollar.
doi:10.1371/journal.pone.0067910.t006
Costs and Outcomes of Pediatric ART
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ranged from $678 to $830 per patient remaining in care during
the first year and $717 to $782 per patient remaining in care
during the second year (in 2009 US dollars). These costs for
pediatric ART in South Africa are substantially higher than the
costs we estimated for pediatric ART in Zambia. This difference
can be explained, at least in part, by higher staffing and fixed costs
in South Africa, which is an upper-middle income country, higher
drug costs, and higher laboratory costs due to the use of viral load
monitoring which is not routinely available in Zambia.
Our study has several limitations. First, results are from six
purposively selected sites. Sites were chosen to capture variation in
location, size, and delivery model, rather than to represent the
ART treatment program in Zambia as a whole. Because sites were
not selected randomly, average costs and retention rates for our
six-site sample should not be taken as an average for the country or
as an average for any particular type of site. Further, because we
have only six sites in our sample, we cannot attribute variation in
costs of care between sites to specific site-level characteristics.
Second, patient outcomes in this analysis are limited to what could
be ascertained from a retrospective review of medical records. For
patients no longer attending the study clinic, we could not always
distinguish between those who had transferred to another clinic,
died, or been lost to follow up due to incomplete records. Third,
we excluded patients known to have transferred to another site
during the study follow up period. These patients may differ
systematically from the study population. Fourth, results are for
average, not marginal, costs. The cost of scaling up any of these six
programs or of opening a new ART clinic based on a similar
model in a similar setting may differ from our estimates. Fifth, we
excluded costs of non-ARV drugs, although such costs, when
estimated, are typically a small share of outpatient costs [8,9].
Sixth, costs of inpatient care, costs incurred before a patient
initiates ART, costs incurred by the patient, and costs for program
management above the facility level were excluded from the
analysis, leading to an underestimate of the total cost to Zambia of
providing pediatric ART. Finally, results reflect the costs and
retention in care for patients who, for the most part, initiated ART
prior to the adoption of early infant diagnosis and treatment
guidelines in Zambia in 2010.
In conclusion, outpatient costs for children initiating ART in
Zambia are low and are comparable to reported outpatient costs
for adults initiating ART in Zambia. Outpatient costs and
retention in care vary widely by site. Exploring such variation
will provide insight into opportunities for efficiency gains through
improvements in retention in care and decreases in service delivery
costs for patients who remain in care. Taking advantage of such
opportunities for efficiency gains will help ensure that targets for
pediatric treatment coverage can be met.
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